Adjuvant taxanes in the treatment of breast cancer: No longer at the tip of the iceberg

被引：17

作者：

Dang, Chau ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Solid Tumor Div, Breast Canc Med Serv, New York, NY 10021 USA

来源：

CLINICAL BREAST CANCER | 2006年 / 7卷 / 01期

关键词：

chemotherapy; docetaxel; hormone receptor status; paclitaxel;

D O I：

10.3816/CBC.2006.n.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Breast cancer is one of the leading causes of cancer-related mortality, and a cure is desperately needed. Adjuvant chemotherapy with anthracycline-based regimens has been proven to decrease the risk of relapse and cancer-related mortality In women with early-stage breast cancer. The taxanes (paclitaxel and docetaxel) have been incorporated into several adjuvant chemotherapy regimens in recent studies. Some of these trials are now mature and have demonstrated a definitive benefit with the use of taxanes. Thus, taxanes should be incorporated into the adjuvant treatment of breast cancer. To date, the available data do not allow one to select a single best taxone, schedule, or overall regimen.

引用

页码：51 / 58

页数：8

共 32 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2]

ALBAIN KS, 2002, P ASCO, V21, P143

[3]

Bear HD, 2004, BREAST CANCER RES TR, V88, pS16

[4]

Berry DA, 2004, BREAST CANCER RES TR, V88, pS17

[5]

Buzdar AU, 2002, CLIN CANCER RES, V8, P1073

[6]

Citron ML, 2005, J CLIN ONCOL, V23, p33S

[7]

Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741 [J].

Citron, ML ;

Berry, DA ;

Cirrincione, C ;

Hudis, C ;

Winer, EP ;

Gradishar, WJ ;

Davidson, NE ;

Martino, S ;

Livingston, R ;

Ingle, JN ;

Perez, EA ;

Carpenter, J ;

Hurd, D ;

Holland, JF ;

Smith, BL ;

Sartor, CI ;

Leung, EH ;

Abrams, J ;

Schilsky, RL ;

Muss, HB ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1431-1439

[8]

Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979

[9]

FISHER B, 1983, CANCER-AM CANCER SOC, V52, P1551, DOI 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO

[10]

2-3

← 1 2 3 4 →